VivoSeq
Dermatology

Acne

29

Pipeline Programs↗

8

Active Trials↗

20

Companies Involved↗

Acne is an emerging landscape with 29 programs across 20 companies. The most active players are Valeant Pharmaceuticals, Vitae Pharmaceuticals Inc., an Allergan affiliate, Astellas. 22 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

97/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Valeant Pharmaceuticals

1 program

Phase 1V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2Pfizer logo

Pfizer

4 programs

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

ApprovedAbbVie logo

AbbVie

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

29 of 31 classified programs — the dominant modality here.

6%ALL OTHERSPeptide13%Vaccine13%

Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.

Analysis

Trial Status

43

clinical trials

Completed30 · 70%
Unknown status4 · 9%
Active, not recruiting3 · 7%
Recruiting3 · 7%
Not yet recruiting2 · 5%
Withdrawn1 · 2%

Clinical Trials

Trial Activity

43 trials

Weekly Isotretinoin vs Tetracycline for Moderate Acne
Recruiting·MMedical University of South Carolina·Phase 1·NCT06225570·50 enrolled
Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients
Recruiting·CCentre for Human Drug Research, Netherlands·Phase 4·NCT03883269·30 enrolled
A Phase 1/2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Participants With Mild Acne
Recruiting·Sanofi logoSanofi·Preclinical·NCT07013747·228 enrolled
Lipidome and Microbiome Profile of Acne
Active, not recruiting·UUniversity of California, Davis·Phase 1/2·NCT02713607·30 enrolled
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
Active, not recruiting·Sun Pharmaceutical Industries Limited logoSun Pharmaceutical Industries Limited·Phase 4·NCT06425900·10 enrolled
The Suitability of Tience® for the Treatment of Acne Scars
Active, not recruiting·LLinio Biotech Oy·Preclinical·NCT07368764·20 enrolled
Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne
Not yet recruiting·SShenzhen People's Hospital·Phase 2·NCT07366229·196 enrolled
A Randomized, Triple-blind, Placebo Controlled, Parallel Virtual Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults
Not yet recruiting·GGenCanna Acquisition Corp·Preclinical·NCT07127523·150 enrolled
P3 Long Term Safety Study of Once Daily SB204 in Acne
Completed·NNovan, Inc.·Phase 3·NCT02798120·601 enrolled
P3 Study in Acne Comparing Once Daily SB204 and Vehicle
Completed·NNovan, Inc.·Phase 3·NCT02672332·1,307 enrolled
Topical ASC-J9 Cream for Acne
Completed·AAndroScience Corp·Phase 2·NCT01289574·181 enrolled
Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne
Completed·—·Phase 4·NCT05704114·20 enrolled
Factors Associated With the Acne Severity Among Transmen Population: a Cross-sectional Study
Completed·MMahidol University·N/A·NCT06149065·247 enrolled
A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
Completed·AbbVie logoAbbVie·Phase 4·NCT01231334·286 enrolled
Long-term Study of Epiduo in Patients With Moderate to Severe Acne
Completed·GGalderma Laboratorium GmbH·N/A·NCT01618773·6,036 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)